Biongevity, a subsidiary of BioAro and a global leader in AI-driven health analytics, genomics, and longevity science, ...

BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. Its proprietary Elion platform integrates ...

Pursuing ISO 9001:2015 certification reflects H.H.C’s ongoing motivation to improve its processes and maintain the trust of its growing client portfolio. This achievement underscores the strength of ...

Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET ...

The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent ...

Ramsay Santé est leader de l'hospitalisation privée et des soins primaires en Europe avec 38 000 salariés et 9 300 praticiens au service de 12 millions de visites patients dans nos 465 établissements ...

In a bold move to combat the mental health crisis facing veterans, ONE Retreats Jamaica, a premier psilocybin-assisted retreat provider, is currently offering a specialized Psilocybin Wellness Program ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company’s Plan to ...

Gustin currently serves as Chief Strategy & Marketing Officer at SpeciCare – New Options in Cancer Care. A recognized industry leader, he has held senior marketing and business management roles across ...

Ramsay Santé is leader in private hospitalisation and primary care in Europe. The Group has 38,000 employees and works with nearly 9,300 practitioners to treat more than 12 million patients per year ...

The Company intends to use the net proceeds raised from the Offering to support sales growth and for working capital and general corporate purposes as further described in the Company’s offering ...

LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announces that it has $15 ...